KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Receivables (2016 - 2026)

Gilead Sciences filings provide 17 years of Change in Receivables readings, the most recent being -$179.0 million for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 148.61% to -$179.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $367.0 million, a 364.03% increase, with the full-year FY2025 number at $367.0 million, up 364.03% from a year prior.
  • Change in Receivables hit -$179.0 million in Q4 2025 for Gilead Sciences, down from $333.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $612.0 million in Q3 2023 to a low of -$975.0 million in Q1 2021.
  • Median Change in Receivables over the past 5 years was $47.5 million (2024), compared with a mean of $8.2 million.
  • Biggest five-year swings in Change in Receivables: plummeted 359.31% in 2021 and later soared 906.9% in 2025.
  • Gilead Sciences' Change in Receivables stood at -$41.0 million in 2021, then surged by 785.37% to $281.0 million in 2022, then crashed by 178.29% to -$220.0 million in 2023, then skyrocketed by 67.27% to -$72.0 million in 2024, then plummeted by 148.61% to -$179.0 million in 2025.
  • The last three reported values for Change in Receivables were -$179.0 million (Q4 2025), $333.0 million (Q3 2025), and $292.0 million (Q2 2025) per Business Quant data.